A cellular signal, not a diagnosis
BRAF is a gene encoding a protein kinase involved in the MAPK signalling pathway. This signalling chain helps regulate cell growth and proliferation. Certain BRAF alterations can keep the signal active when it should not be and can become a drug target.
V600E describes replacement of valine by glutamic acid at position 600 of the protein. In current nomenclature, on reference transcript NM_004333.6, it corresponds to c.1799T>A, p.Val600Glu. Older documents may use previous numbering: interpreting a report requires the gene, variant and reference sequence used.
Sources for this section: NCBI ClinVar — BRAF c.1799T>A, p.Val600Glu; National Cancer Institute — Melanoma Treatment (PDQ), health professional version.
Tumour testing and its limitations
BRAF testing is performed when it can guide treatment, using validated methods and adequate material. A single commercial brand should not be described as the only possible test. The laboratory and pathologist assess specimen quality, tumour-cell content and the method’s ability to detect relevant variants.
V600E is not the only BRAF variant: V600K and non-V600 alterations also exist and must not automatically be treated as equivalent. A negative result also depends on what the assay tests for and specimen quality. With incomplete or discordant results, the specialist may consider further testing; the report is not interpreted in isolation.
Sources for this section: ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025); EMA — Tafinlar: indications, product information and leaflet; EMA — Zelboraf: indications, product information and leaflet.
When the result changes treatment options
BRAF V600 positivity may make combinations blocking BRAF and MEK available, including dabrafenib with trametinib and vemurafenib with cobimetinib. Evidence for one pair does not justify constructing different combinations. Indication, stage, previous treatment and individual circumstances remain decisive.
Immunotherapy can also be used in BRAF-mutated melanoma. Choice and sequence cannot be inferred from the test alone: progression rate, symptoms, disease sites, overall health and contraindications matter. DREAMseq informs discussion of sequences in the population studied without establishing an unvarying rule for every patient.
Sources for this section: DREAMseq — Randomized treatment-sequence trial (2022/2023); ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025); EMA — Cotellic: indications, product information and leaflet; EMA — Mekinist: indications, product information and leaflet.
Somatic mutation, family history and research
A mutation found in a tumour does not automatically show that it is inherited or present throughout the body. Assessment of familial predisposition is a separate pathway based on personal and family history and, when indicated, genetic counselling. BRAF V600E alone is not a screening test for relatives.
Likewise, a molecular target does not replace histological examination and staging. Studies of new combinations, resistance or less common variants must be distinguished from established indications. Ask for the report and treatment proposal to be explained together: “which variant was found, which option does it make possible and what alternatives remain?”.
Sources for this section: ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025); NCBI ClinVar — BRAF c.1799T>A, p.Val600Glu; National Cancer Institute — Participate in Cancer Treatment Trials.
Sources and update
- NCBI ClinVar — BRAF c.1799T>A, p.Val600Glu
- National Cancer Institute — Melanoma Treatment (PDQ), health professional version
- ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025)
- EMA — Tafinlar: indications, product information and leaflet
- EMA — Zelboraf: indications, product information and leaflet
- DREAMseq — Randomized treatment-sequence trial (2022/2023)
- EMA — Cotellic: indications, product information and leaflet
- EMA — Mekinist: indications, product information and leaflet
- National Cancer Institute — Participate in Cancer Treatment Trials
Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.
